



ASX Release

Acrux and Harris terminate license agreement

Melbourne, Australia; 11 October 2021

Subsequent to Harris Pharmaceutical Inc ('Harris') filing for a Chapter 11, Subchapter V bankruptcy in the United States Bankruptcy Court, Middle District of Florida, Acrux and Harris have mutually terminated the license agreement for Prilocaine 2.5% and Lidocaine 2.5% cream. Acrux had entered into an exclusive sales, marketing and distribution agreement with Harris in August 2020.

Acrux is currently negotiating a licensing agreement for the commercialisation of the product with another specialist generic company in the United States.

The Acrux ANDA is a generic of EMLA® (lidocaine 2.5% and prilocaine 2.5%) cream and was approved by the FDA in July 2021.

Approved for release by the Acrux Board of Directors.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: +61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au